Profile data is unavailable for this security.
About the company
Pulike Biological Engineering. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The Company's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
- Revenue in CNY (TTM)1.18bn
- Net income in CNY136.36m
- Incorporated2002
- Employees1.68k
- LocationPulike Biological Engineering IncNo. 15, Zhenghe Road, Luolong DistrictLUOYANG 471000ChinaCHN
- Phone+86 37 963282386
- Fax+86 37 963282386
- Websitehttp://www.pulike.com.cn/
More ▼
Mergers & acquisitions
| Acquired company | 603566:SHH since announced | Transaction value |
|---|---|---|
| Luoyang Lechong Health Technology Co Ltd | -38.11% | 3.24m |
Data delayed at least 15 minutes, as of Jun 21 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Kawin Technol Sha-hld Co Ltd | 1.43bn | 117.53m | 4.60bn | 584.00 | 38.10 | 2.54 | -- | 3.21 | 0.7061 | 0.7061 | 8.61 | 10.60 | 0.6264 | 1.66 | 4.42 | 2,451,945.00 | 6.11 | 5.31 | 7.69 | 6.76 | 82.35 | 86.02 | 9.76 | 8.10 | 3.25 | -- | 0.0809 | 43.82 | 21.73 | 14.87 | 39.71 | 21.04 | 25.01 | -- |
| GemPharmatech Co Ltd | 638.97m | 157.34m | 4.60bn | 1.51k | 29.26 | 2.16 | -- | 7.21 | 0.3838 | 0.3838 | 1.56 | 5.20 | 0.2617 | 4.11 | 2.36 | 424,282.40 | 6.44 | 9.45 | 7.28 | 11.13 | 66.43 | 70.21 | 24.62 | 28.16 | 4.68 | -- | 0.0592 | 14.68 | 20.45 | 63.48 | -3.48 | -- | 141.38 | -- |
| InventisBio Co Ltd | 194.13m | -249.28m | 4.67bn | 221.00 | -- | 2.41 | -- | 24.03 | -0.4289 | -0.4289 | 0.3348 | 3.35 | 0.0898 | -- | 1.96 | 878,429.50 | -11.53 | -- | -12.26 | -- | 97.85 | -- | -128.41 | -- | -- | -- | 0.0054 | -- | -- | -- | 41.26 | -- | -- | -- |
| HitGen Inc | 409.13m | 64.05m | 4.75bn | 452.00 | 74.00 | 3.45 | -- | 11.61 | 0.1601 | 0.1601 | 1.02 | 3.44 | 0.241 | 6.70 | 4.84 | 905,165.50 | 3.77 | 4.63 | 4.02 | 5.10 | 51.46 | 58.89 | 15.66 | 20.66 | 14.48 | 360.77 | 0.142 | 19.14 | 12.64 | 19.69 | 61.16 | -1.96 | -6.12 | -- |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 799.09m | 269.00m | 4.90bn | 1.14k | 17.67 | 2.11 | -- | 6.13 | 1.37 | 1.37 | 4.08 | 11.49 | 0.2573 | 0.9016 | 6.83 | 699,118.90 | 8.66 | 10.04 | 10.48 | 11.63 | 81.31 | 83.66 | 33.66 | 28.29 | 3.33 | -- | 0.2547 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
| Pulike Biological Engineering Inc | 1.18bn | 136.36m | 4.98bn | 1.68k | 36.47 | 1.82 | -- | 4.21 | 0.3946 | 0.3946 | 3.39 | 7.91 | 0.359 | 2.39 | 2.65 | 704,310.60 | 4.14 | 7.64 | 4.81 | 8.96 | 60.96 | 62.57 | 11.53 | 17.85 | 2.58 | 148.40 | 0.0146 | 52.48 | 1.84 | 15.55 | 3.99 | 5.17 | 41.58 | 18.47 |
| Shanghai Yizhong Pharmaceutical Co Ltd | 336.56m | 135.71m | 5.16bn | 43.00 | 38.02 | 3.44 | -- | 15.34 | 0.66 | 0.66 | 1.64 | 7.28 | 0.2219 | 0.9416 | 3.28 | 7,826,913.00 | 8.95 | -0.9181 | 9.39 | -0.9485 | 93.54 | 93.19 | 40.32 | -6.11 | 12.66 | -- | 0.0342 | -- | 52.68 | -- | 13.09 | -- | 20.44 | -- |
| Guizhou Sanli Pharmaceutical Co Ltd | 1.71bn | 293.82m | 5.25bn | 2.28k | 18.33 | 3.37 | -- | 3.07 | 0.6988 | 0.6988 | 4.11 | 3.80 | 0.7064 | 2.58 | 3.81 | 748,477.00 | 12.34 | 12.39 | 18.37 | 16.72 | 71.52 | 70.45 | 17.47 | 16.31 | 1.67 | -- | 0.2368 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Beijing Sun-Novo Pharma Research Co Ltd | 951.95m | 209.57m | 5.29bn | 1.37k | 25.25 | 5.22 | -- | 5.56 | 1.87 | 1.87 | 8.50 | 9.06 | 0.5465 | 26.19 | 1.77 | 694,854.30 | 11.70 | 12.99 | 19.13 | 21.70 | 59.10 | 53.93 | 21.40 | 21.34 | 1.77 | 45.00 | 0.3721 | 10.74 | 37.76 | 47.22 | 18.08 | 54.90 | 34.77 | -- |
Data as of Jun 21 2024. Currency figures normalised to Pulike Biological Engineering Inc's reporting currency: Chinese Yuan Renminbi CNY
7.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Origin Asset Management Co. Ltd.as of 17 Mar 2023 | 5.39m | 1.53% |
| Harvest Fund Management Co., Ltd.as of 17 Mar 2023 | 4.06m | 1.16% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 3.92m | 1.12% |
| AXA-SPDB Investment Managers Co., Ltd.as of 31 Dec 2023 | 2.76m | 0.79% |
| Da Cheng Fund Management Co., Ltd.as of 31 Dec 2023 | 2.30m | 0.66% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 1.74m | 0.50% |
| JPMorgan Chase Bank, NA (Investment Management)as of 17 Mar 2023 | 1.68m | 0.48% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 1.33m | 0.38% |
| Soochow Asset Management Co., Ltd.as of 17 Mar 2023 | 1.12m | 0.32% |
| CITIC-Prudential Fund Management Co., Ltd.as of 31 Dec 2023 | 1.06m | 0.30% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
